secwatch.observer — SEC 8-K summary
======================================

Issuer:     Marker Therapeutics, Inc. (MRKR)
CIK:        0001094038
Form:       8-K
Filed at:   2026-10-19T11:12:47+00:00
Accession:  0001104659-26-116720
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Marker Therapeutics wins $2.6M FDA orphan grant for MT-601 pancreatic cancer trial
--------------------------------------------------------------------------------

- FDA awarded Marker Therapeutics $2.6 million under its Orphan Products Clinical Trials grants program to support a Phase 1 study of MT-601 in locally advanced unresectable pancreatic cancer.
- FDA received 66 applications for the FY2026 orphan products program and selected six, including Marker's MT-601 project.
- Marker plans to initiate the company-sponsored pancreatic cancer study in Q1 2027, using expanded antigen targeting, higher T-cell doses, and lymphodepletion.
- Prior Baylor Phase 1/2 data in Nature Medicine showed 84.6% disease control, 7.5-month median duration of response, and 14.1-month median overall survival.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1094038/000110465926116720/0001104659-26-116720-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1094038/000110465926116720/tm2627740d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-116720

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer